Clinical Trial Update: Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety of dasatinib in patients with scleroderma-associated pulmonary fibrosis. The study has completed and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Systemic Sclerosis

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Scleroderma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-02-29